Evidence map›Paper›PMID 35819845›Full record

ArticleBiochemistry2022

Discovery and Characterization of a Novel Allosteric Small-Molecule Inhibitor of NADP

Tomohiro Yoshida, Tetsuhiro Kawabe, Lewis C Cantley, Costas A Lyssiotis

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. A cryptic allosteric pocket shapes isoform-selective inhibition of human malic enzymes.Protein science : a publication of the Protein Society · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Significance of Malic Enzyme 1 in Cancer: A Review.Current issues in molecular biology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Tomohiro YoshidaBusiness Development, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan.
Tetsuhiro KawabeApplied Research & Operations, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan.
Lewis C CantleyMeyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, United States.
Costas A LyssiotisDepartment of Molecular & Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology, and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0001-9309-6141
Astellas Pharma (Japan) · JPCornell University · USUniversity of Michigan · US

Funding

Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2M
NCI NIH HHS R35 CA197588
6 · The paper itself

Abstract

NADP

Indexed as

Malate DehydrogenaseMalatesAllosteric SiteNADPMalate Dehydrogenasemalate dehydrogenase (decarboxylating)MalatesNADP

Identifiers

PMID35819845
PMCPMC9352307
OpenAlexW4285076950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.